Background. Cough is a common presenting symptom in patients with idiopathic interstitial pneumonia (IIP); it is often disabling, and lacks effective treatment. Studies in animals suggest that carcainium chloride, a quaternary derivative of the local anesthetic lidocaine, is able to inhibit experimentally induced cough by a mechanism of action distinct from that of lidocaine.
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Abstract
Background. Cough is a common presenting symptom in patients with idiopathic interstitial pneumonia (IIP); it is often disabling, and lacks effective treatment. Studies in animals suggest that carcainium chloride, a quaternary derivative of the local anesthetic lidocaine, is able to inhibit experimentally induced cough by a mechanism of action distinct from that of lidocaine.
Objective. To determine the effectiveness of aerosolised carcainium chloride (VRP700) in controlling cough in patients with IIP.
Methods: Eight female patients (mean age 71 years) with IIP were investigated in a double blind, randomised, placebo controlled crossover, adaptive contingency study design (EudraCT Number 2010-021350-19). The study consisted of a screening visit to assess the eligibility of patients, and two separated (48-72 hours) study days. On the two study days, patients were randomised to receive either nebulized VRP700 (1.0 mg/kg) on the first study visit followed by nebulised placebo (sodium chloride 0.9%) on the second visit, or placebo on the first visit followed by VRP700 on the second visit. The primary endpoint was cough frequency over a 4-hour assessment period; secondary endpoints were subjective coughrelated level of discomfort as assessed by a visual analogue scale (VAS) and the subjective response to treatment as assessed by a quality of life question. Safety (ECG, spirometry, urine and blood tests) and adverse events occurring during the trial were also investigated.
Results. In all patients both VRP700 and placebo decreased cough frequency; however, mean decreases in cough frequency after treatment with VRP700 were significantly (P<0.001) higher than with placebo. Similarly, mean reductions in VAS score were significantly (P<0.001) higher after treatment with VRP 700 compared with placebo. All but one patient indicated that they felt better after receiving VRP700. No adverse events M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 3 were reported during the study, nor were any changes in ECG variables, spirometry, urine and blood tests noted.
Conclusion. The results of this exploratory study indicate that nebulised VRP700 improved cough and quality of life in hospitalised IIP patients with no significant side effects. A larger trial is warranted to assess these promising results.
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Introduction
Chronic cough remains a serious unmet medical need [1, 2] . Cough is a nerve reflex involving the activation of vagally innervated receptors ultimately resulting in cough motor events [3] . Receptors (sensors) implicated in the cough reflex have been found on families of both thin myelinated (Aδ) and unmyelinated bronchial and pulmonary C sensory nerve fibres [4, 5] . Not surprisingly, therefore, local anaesthetics can inhibit coughing presumably via inhibition of conduction of these sensory nerve fibers [6] , but they are known to interfere with other important protective reflexes such as the gag reflex [7] , limiting their wider use in the clinic.
Carcainium chloride, that is structurally related to the local anaesthetic lidocaine [8] , has been reported to reduce cough responses in guinea pigs and rabbits by selective inhibition of Aδ fibres when applied topically to the airways, whilst having no inhibitory effect on bronchial or pulmonary C-fibres, which were both inhibited by topical lidocaine [9] . To our knowledge, this selectivity for Aδ fibres has not been reported so far for other drug classes.
However, to date no studies investigating the effect of inhaled carcainium chloride on cough responses have been reported in humans.
This pilot study, therefore, aimed to investigate the effectiveness of inhaled carcainium chloride (hereafter named VRP700) in controlling cough of patients with idiopathic interstitial pneumonia (IIP) [10] . Patients with IIPs were chosen since cough is a distressing and disabling symptom of this disease [10] .
Methods

Study design and participants
This was a randomised, double blind, crossover, placebo controlled study performed according to an adaptive contingency design [11] . We enrolled adult, non-smoking inpatients with IIP and refractory chronic cough [12] . We excluded patients who reported <1 month respiratory tract infections, who were taking an angiotensin-converting enzyme inhibitor, or who had liver or renal dysfunction. Women breastfeeding or of childbearing age were also excluded. Written consent was obtained from each patient; the study was approved by the Ethics Committee of the Careggi Hospital (EudraCT number 2010-021350-19).
Protocol and Recording Procedures
After screening, each patient was examined on two separate (48-72 hours) occasions adverse events were reported. Blood and urine samples were collected for standard safety laboratory assessments; blood samples were also taken at baseline, at 20, 40, 60, 90, 120 minutes and 3, 4 hours after VRP700 inhalation to calculate the maximum plasma concentration (C max ) and time to reach C max (T max ) [14] .
Data Analysis
The primary outcome variable was cough frequency over a 4-hour assessment period measured before and after VRP700 and placebo administration; secondary outcome variables were VAS scores, patients' subjective response and physicians' judgement.
Categorical data were expressed as percentages, whereas normal distributed data were presented as mean ±SD. For efficacy parameters, all tests for a difference between the two treatments have been two-sided and performed at the 5% significance level.
Results
Eight female patients (Table) completed the study with no significant changes in vital signs, ECG variables, spirometry, as well as in any parameters measured in blood or urine.
Preliminary CT scans indicated that six patients suffered from usual interstitial pneumonia, one had non-specific interstitial lung disease, and another one had an unclassifiable IIP. No patients reported adverse events during the study. However, they consistently coughed more during the 1 st or 2 nd minutes of nebulisation of active drug, followed by a marked decrease in cough over the rest of nebulisation period. As the cough monitor was not started until after inhalation had completed, these initial coughs have not been recorded.
In the patients as a group, C max for VRP700 ranged from 2.26 to 37.7 ng/mL with a T max of 20 min.
VRP700 significantly decreased cough frequency from 57.75±15.51 cph to 13.13±9.62 cph four hours after VRP700 administration (p<0.001, Figure 2 ). With placebo, the same M A N U S C R I P T All patients indicated that they felt better after receiving VRP700. Only 1 patient felt better after receiving placebo and one felt worse: the remaining patient reported no appreciable change; so that the difference between the 2 treatments was statistically significant (P<0.02 by Chi squared). In all patients, physicians selected VRP700 as being the more effective (P<0.01) treatment in reducing the patient's cough frequency.
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Discussion
We have demonstrated a marked antitussive effect of nebulised VRP700 in patients with chronic cough and IIP with an overall 80% reduction in cough frequency. Patients also reported a remarkable subjective improvement, also confirmed by medical evaluation. VRP700 appears to be safe since none of the patients reported any clinically relevant side effect, notably no paraesthesia that has been reported following treatment with local anaesthetics.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 8
One limitation of the crossover study design is the so-called carry over effect [15] .
Indeed, four patients showed a larger reduction in cough frequency and VAS score when they received the sequence VRP700-placebo rather than the sequence placebo-VRP700, thus suggesting that prior exposure to the active drug may have enhanced the subsequent responses to placebo. However, overall, the active drug proved to be far more effective than placebo in the patients as a group, although there were insufficient samples to test for statistical significance of the sequence effect in the study population. On the other hand, the advantage of the statistical method used here [11] is that it does not require an initial commitment to a large sample size, since the ultimate sample size was determined by the data generated during the study.
The reason for female patients being studied reflected that patient recruitment was consecutive, and the greater severity of the disease in females [16] may have contributed.
The exact mechanism(s) underlying cough in IIP remains unclear [17] . For instance, more than 50% of patients with interstitial lung disease could have cough caused by other causes such as asthma, rhinitis or gastro-oesophageal reflux [18, 19] . However, IIP may directly cause cough as inflammation is not limited to the parenchyma, and disrupted airway epithelium [20] with inflammatory mediators known to provoke cough having been detected in such patients [17, 18] . A further possible cause of cough in patients with IIP is airway distortion secondary to interstitial fibrosis, which results in traction bronchiectasis [21] .
Whilst the molecular mechanism of action of VRP700 remains incompletely understood, this is highly unlikely to be due to any local anaesthetic activity of this drug as it has a distinct electrophysiological profile from lidocaine on airway sensory nerves [9] . In addition, VRP700 inhibits the activation of airway Aδ fibres selectively [9] , a finding in keeping with a major role for Aδ fibres in many patients with chronic cough.
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The antitussive effect of VRP700 is comparable to that recently reported using a P2X3 purinergic receptor antagonist (AF-219) in patients with refractory chronic cough [22] .
However, unlike AF-219, which was associated with loss of taste in the majority of patients, VRP700 was not associated with any major side effects.
In conclusion, VRP700 may be promising and safe in patients with IIP. Whether the drug is also suitable for long-term administration and in the management of patients with intractable cough of different origin remains to be ascertained.
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